Literature DB >> 3453897

Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies.

Y Frei1, J D Lambris, B Stockinger.   

Abstract

We have generated a monoclonal antibody with specificity for the fifth component of mouse complement (C5). This antibody precipitates the two chains of C5 from normal mouse serum and inhibits C5-dependent hemolysis in a functional complement test. In this study we describe its application in an enzyme-linked immunoadsorbent assay (ELISA assay) for the detection of anti-C5 antibodies in serum. Monoclonal anti-C5 coupled to wells of an ELISA plate specifically binds C5 from unfractionated normal mouse serum. This subsequently serves as antigen to bind anti-C5 serum antibodies. By this approach we have circumvented the need for extensive purification of C5 from serum which would be required if C5 was directly coupled to ELISA plates as antigen. Serum antibodies from C5-immunized mice bound with high avidity to wells containing normal serum as antigen source in amounts representing 1 microgram to 250 ng C5. There was no antibody binding to wells containing C5-deficient serum as antigen source. The immune reaction was detected by development with enzyme-coupled goat-anti mouse Ig antibodies specific for various mouse Ig subclasses. This method allows the qualitative characterization of immune responses to mouse C5 which is an ideal model for a natural self antigen in studies of immunological tolerance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3453897     DOI: 10.1016/0890-8508(87)90022-3

Source DB:  PubMed          Journal:  Mol Cell Probes        ISSN: 0890-8508            Impact factor:   2.365


  34 in total

1.  A protective role for the fifth complement component (c5) in allergic airway disease.

Authors:  Scott M Drouin; Meenal Sinha; Georgia Sfyroera; John D Lambris; Rick A Wetsel
Journal:  Am J Respir Crit Care Med       Date:  2006-01-26       Impact factor: 21.405

Review 2.  Complement-targeted therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Nat Biotechnol       Date:  2007-11       Impact factor: 54.908

3.  Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury.

Authors:  Jennifer Laskowski; Brandon Renner; Moglie Le Quintrec; Sarah Panzer; Jonathan P Hannan; Danica Ljubanovic; Marieta M Ruseva; Dorin-Bogdan Borza; Alexandra H Antonioli; Matthew C Pickering; V Michael Holers; Joshua M Thurman
Journal:  Kidney Int       Date:  2016-05-07       Impact factor: 10.612

Review 4.  Clinical promise of next-generation complement therapeutics.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Rev Drug Discov       Date:  2019-07-19       Impact factor: 84.694

5.  From functions to mechanisms of the prototypic complement C5 antibody BB5.1.

Authors:  Simon Milling
Journal:  Immunology       Date:  2020-10       Impact factor: 7.397

6.  Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis.

Authors:  Harald F Langer; Kyoung-Jin Chung; Valeria V Orlova; Eun Young Choi; Sunil Kaul; Michael J Kruhlak; Markella Alatsatianos; Robert A DeAngelis; Paul A Roche; Paola Magotti; Xuri Li; Matina Economopoulou; Stavros Rafail; John D Lambris; Triantafyllos Chavakis
Journal:  Blood       Date:  2010-07-12       Impact factor: 22.113

7.  Anti-complement component C5 mAb synergizes with CTLA4Ig to inhibit alloreactive T cells and prolong cardiac allograft survival in mice.

Authors:  H Raedler; M B Vieyra; S Leisman; P Lakhani; W Kwan; M Yang; K Johnson; S J Faas; P Tamburini; P S Heeger
Journal:  Am J Transplant       Date:  2011-06-10       Impact factor: 8.086

Review 8.  Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; Antonio M Risitano; John D Lambris
Journal:  Semin Hematol       Date:  2018-02-14       Impact factor: 3.851

9.  Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.

Authors:  D A Copland; K Hussain; S Baalasubramanian; T R Hughes; B P Morgan; H Xu; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

10.  Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.

Authors:  Guillermina Girardi; Jessica Berman; Patricia Redecha; Lynn Spruce; Joshua M Thurman; Damian Kraus; Travis J Hollmann; Paolo Casali; Michael C Caroll; Rick A Wetsel; John D Lambris; V Michael Holers; Jane E Salmon
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.